Hikma Pharmaceuticals Regulatory News (HIK)

London, 20 April 2022 - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today confirms it has received preliminary approval from the US Federal Trade Commission (FTC) and will now work towards closing its acquisition of Custopharm Inc. from Water Street Healthcare Partners, as previously announced on 27 September 2021. The parties have now obtained all regulatory approvals required to close the transaction. Hikma will make a further announcement upon the close of the transaction.

- ENDS -

Enquiries:

Hikma (Investors):

Teneo (Press):

About Hikma(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com